Challenges and considerations in the immunotherapy of DLL3-positive small-cell lung cancer using IL-18 armoured chimeric antigen receptor T-cells.

Mazza, Roberta; Maher, John; Hull, Caroline M

Mazza, Roberta; Maher, John; Hull, Caroline M.

Affiliation

Mazza R; Leucid Bio Ltd., Guy's Hospital, London, UK.
Maher J; Leucid Bio Ltd., Guy's Hospital, London, UK.
Hull CM; School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Hospital, London, UK.

Transl Lung Cancer Res ; 13(3): 678-683, 2024 Mar 29.

Article in En | MEDLINE | ID: mdl-38601439

Key words

Delta-like ligand 3 (DLL3); armoured CAR T-cells; immunotherapy; interleukin-18-secreting chimeric antigen receptor T-cells (IL-18-secreting CAR T-cells); small-cell lung cancer (SCLC)

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Transl Lung Cancer Res Year: 2024 Type: Article

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Transl Lung Cancer Res Year: 2024 Type: Article